Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.
A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.
The checkpoint inhibitor is approved for adults and children with relapsed lymphoma.
The immunotherapy combo improved overall survival compared with chemotherapy.
Among urothelial cancer patients treated with atezolizumab, those who used PPIs had a 68 percent greater risk of death.
Opdivo plus Cabometyx reduced the risk of death by 40%.
New research discusses how immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient.
A Phase 1 study on customized immunotherapy shows promise for people with lung cancer.
A recent clinical trial found that the combination did not work.
Nearly half of patients treated with the combination saw their tumors shrink in an early study.
Tecentriq plus two targeted medications extended progression-free survival by 4.5 months.
Instead of researching new treatment targets or experimental combination therapies, she focuses on patient experience and quality of life.
The combination improved both overall survival and patient-reported outcomes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.